In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioSpace
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Wall Street Online
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on fibrotic disease processes, a key focus area of Boehringer Ingelheim.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Yahoo! Finance
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model launched today – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Access Wire
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on wound healing & fibrosis.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Open PR
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
PharmiWeb
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Access Wire
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Finanz Nachrichten
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Yahoo! Finance
BioMed X, an independent biomedical research institute, announces the start of its new research project – “New Strategies to Enhance the Immunogenicity of Tumors” – in collaboration with Merck. The focus of this new research group will be to develop novel approaches for enhancing tumor immunogenicity to broaden the population of patients who could benefit from cancer immunotherapy.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioSpace
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
StartupHub.ai
AION Labs, a pioneering innovation lab dedicated to utilizing AI technologies and computational science for tackling therapeutic challenges, and BioMed X, an independent German research institute, have announced their 2023 global call for applications. They are seeking talented technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
PR Newswire
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
BioSpace
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: AION Labs launches second startup focused on AI-enabled antibody design
AION Labs launches second startup focused on AI-enabled antibody design
MobiHealthNews
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Visit: AION Labs Launches AI Startup for De Novo Antibody Design
AION Labs Launches AI Startup for De Novo Antibody Design
PR Newswire
DenovAI is the second company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X.
Visit: Israel lab backed by pharma giants mints startup for computer-designed antibodies
Israel lab backed by pharma giants mints startup for computer-designed antibodies
Times of Israel
AION Labs, a consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company to build a computational platform to design live-saving antibodies from scratch
Visit: New Israeli company aims to design life-saving proteins from scratch
New Israeli company aims to design life-saving proteins from scratch
The Jerusalem Post
DenovAI is approved by the Israel Innovation Authority and will receive a $2 million grant from AION Labs and its investment partners Pfizer, AstraZeneca, Merck, Teva and Israel Biotech Fund.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Word Pharma Today
BioMed X unveiled its new immunology discovery platform designed to allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs).
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Contract Pharma
The new technology functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Yahoo!
A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.